Susan D. Wyrick - 05 Mar 2026 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Signature
/s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick
Issuer symbol
SANA
Transactions as of
05 Mar 2026
Net transactions value
$0
Form type
4
Filing time
06 Mar 2026, 16:53:37 UTC
Previous filing
04 Mar 2026
Next filing
10 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wyrick Susan D. SVP, Finance and Accounting and Principal Accounting Officer C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 350, SEATTLE /s/ Aaron M. Grossman, Attorney-in-Fact for Susan D. Wyrick 06 Mar 2026 0001568605

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Restricted Stock Units Award +45,833 $0.000000* 45,833 05 Mar 2026 Common Stock 45,833 Direct F1, F2
transaction SANA Stock Option (Right to Buy) Award +206,250 $0.000000* 206,250 05 Mar 2026 Common Stock 206,250 $3.41 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2 The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Remarks:

SVP, Finance and Accounting and Principal Accounting Officer